PMID: 8971469Nov 1, 1996Paper

Monoclonal antibody-based therapy

Current Opinion in Oncology
M von Mehren, L M Weiner

Abstract

Monoclonal antibodies have been developed for cancer therapy because they specifically target tumor-related antigens. The current design of antibodies and delivery strategies seeks to overcome the obstacles encountered in delivering antibodies to their targets. Protein engineering techniques to humanize murine antibodies diminishes the immune response, which develops against murine monoclonal antibodies, allowing for multiple doses. Antibodies linked to vasoactive substances or conjugated to liposomes increase antibody and drug localization to tumors. Altering the sizes of antibodies and the methods by which they are conjugated to radioactive isotopes have delineated methods to increase efficacy and decrease toxicity. Tumor growth factors increasingly are being targeted by antibody-based therapeutics. To enhance immune activation of cytotoxic effector cells, bispecific antibodies and antibodies linked to superantigens are being examined. Prodrugs are being converted to their active compounds at the tumor site by antibodies conjugated to enzymes. Finally, intrabodies which can bind to intracellular proteins and are important for the malignant phenotype of the cell, are being developed.

Citations

Apr 25, 2012·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·Thomas PoeschingerWerner Scheuer
Apr 21, 1999·Biochimica Et Biophysica Acta·R H van der LindenC T Verrips
Jun 6, 2000·Advanced Drug Delivery Reviews·B PerssonR K Alpaugh
Aug 1, 1997·Current Opinion in Biotechnology·P Carter, A M Merchant
Jul 27, 2001·Cancer Biotherapy & Radiopharmaceuticals·S K Imam
May 7, 2002·Hybridoma and Hybridomics·Leslie A KhawliAlan L Epstein
Apr 25, 2000·Gastroenterology Nursing : the Official Journal of the Society of Gastroenterology Nurses and Associates·L B Hurd, G R Lichtenstein
Sep 21, 2004·Applied Microbiology and Biotechnology·Vivi JoostenB Christien Lokman
Jul 5, 2005·Expert Opinion on Investigational Drugs·D L DrakemanP K Wallace
Jun 30, 2000·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·A J BremersG Parmiani

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Maria Luisa Veronese, Peter J O'Dwyer
Current Opinion in Biotechnology
P J Hudson
© 2021 Meta ULC. All rights reserved